Supernus Pharm (SUPN) Tops Q1 EPS by 3c

Supernus Pharm (NASDAQ: SUPN) reported Q1 EPS of ($0.38), $0.03 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $9 million versus the consensus estimate of $9.94 million.

For earnings history and earnings-related data on Supernus Pharm (SUPN) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
• SpaceX receives Baa1 rating from Moody's with stable outlook